Treatment for Children and Adolescents with Hodgkin Lymphoma
A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy
This study is testing different chemotherapy treatments for children and teens with newly diagnosed Hodgkin lymphoma to see how well they work and improve their chances of staying healthy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | Children's Cancer Group, China Research network |
| Drugs / interventions | chemotherapy, Prednisone, cyclophosphamide, doxorubicin |
| Locations | 3 sites (Chengdu and 2 other locations) |
| Trial ID | NCT04726501 on ClinicalTrials.gov |
What this trial studies
This study focuses on children and adolescents aged 1 to 18 years who have been newly diagnosed with Hodgkin lymphoma. Patients are stratified into three risk groups based on established criteria and receive a combination of chemotherapy treatments, with some also undergoing involved-field radiotherapy depending on their response to initial treatment. The goal is to evaluate the effectiveness of these treatment regimens in achieving event-free and overall survival rates, while also identifying areas for improvement in clinical care for Hodgkin lymphoma in China. The study aims to contribute to future innovative clinical research in this area.
Who should consider this trial
Good fit: Ideal candidates are children and adolescents aged 1 to 18 years with newly diagnosed and biopsy-proven Hodgkin lymphoma.
Not a fit: Patients who have received prior chemotherapy for their current diagnosis or have severe underlying health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes and survival rates for children and adolescents with Hodgkin lymphoma.
How similar studies have performed: Other studies have shown success with similar chemotherapy protocols in treating Hodgkin lymphoma, but this specific approach in the Chinese pediatric population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must be ages 1 to 18 years at the time of diagnosis; Newly diagnosed, histologically confirmed Hodgkin disease (No nodular lymphocyte-predominant Hodgkin lymphoma) Exclusion Criteria: * Patients have received prior cytotoxic chemotherapy for the current diagnosis or any cancer, if any steroid applied, total prior steroids dosage \< Prednisone 80 mg/m2; Patients have congenital immunodeficiency, HIV infection, or prior organ transplant; Patients have overwhelming infection, and a life expectancy of \< 2 weeks
Where this trial is running
Chengdu and 2 other locations
- West China Second University Hospital, Sichuan University, Chengdu, China — Chengdu, China (Recruiting)
- Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China — Nanjing, China (Recruiting)
- Shanghai Children's Medical Center — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Yi-Jin Gao
- Email: gaoyijin@scmc.com.cn
- Phone: 0086-21-38626161
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.